Unifying On Immunotherapy: Will It Pay Off?
This article was originally published in Scrip
It's too early to know now whether the $250m billionaire tech entrepreneur Sean Parker is pumping into immunotherapy will pay off.
You may also be interested in...
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.